STOCK TITAN

LONZA GROUP AG UNSP/ADR - LZAGY STOCK NEWS

Welcome to our dedicated page for LONZA GROUP UNSP/ADR news (Ticker: LZAGY), a resource for investors and traders seeking the latest updates and insights on LONZA GROUP UNSP/ADR stock.

LONZA GROUP AG UNSP/ADR (LZAGY) is a leading global company that specializes in life sciences and healthcare solutions. With a focus on innovation, Lonza provides a wide range of products and services, including pharmaceuticals, biotechnology, nutrition, and cosmetics. The company's cutting-edge technologies and state-of-the-art facilities enable them to deliver high-quality solutions to customers worldwide. Lonza's commitment to sustainability and excellence in research and development sets them apart in the industry.

Rhea-AI Summary

Synaffix and Elevation Oncology have entered into a licensing agreement for ADC (antibody-drug conjugate) technology development. The deal grants Elevation Oncology access to Synaffix's clinical-stage ADC platform, including GlycoConnect®, HydraSpace®, and toxSYN® technologies, to develop a novel HER3 ADC candidate named EO-1022.

Under the agreement terms, Synaffix could receive up to $368 million in upfront and milestone payments, plus tiered royalties on net sales. Synaffix will manufacture technology components while Elevation Oncology handles research, development, manufacturing, and commercialization of the ADC. The partnership aims to develop treatments for patients with HER3-expressing solid tumors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.58%
Tags
none
-
Rhea-AI Summary

Elevation Oncology (ELEV) has nominated EO-1022 as its HER3 ADC development candidate for treating HER3-expressing solid tumors. EO-1022 combines seribantumab, an anti-HER3 monoclonal antibody, with an MMAE payload using Synaffix's technology platform. The company has secured a global license agreement with Synaffix for their GlycoConnect®, HydraSpace®, and SYNstatin E™ technologies.

HER3 is expressed in various cancers including breast cancer, EGFR-mutant non-small cell lung cancer, and pancreatic cancer. The company plans to present preclinical data in 1H 2025 and file an IND application in 2026. Seribantumab has already demonstrated a well-tolerated safety profile in over 900 patients across multiple studies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.58%
Tags
none
-
Rhea-AI Summary

Lonza's Synaffix has licensed its ADC technology to BigHat Biosciences following successful preclinical studies. The collaboration combines BigHat's AI/ML-powered antibody design platform, Milliner™, with Synaffix's GlycoConnect™, HydraSpace® and toxSYN® ADC technologies to develop next-generation ADCs. Through Lonza's acquisition of Synaffix, BigHat gains access to Lonza's comprehensive DNA-to-IND ADC development and manufacturing services. The partnership aims to advance BigHat's next-gen ADC program, which is currently at IND-enabling stage and set to become BigHat's first clinical stage program.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
none
Rhea-AI Summary

NeuroSense Therapeutics (Nasdaq: NRSN) provides a business update for Q1 2024, highlighting key collaborations and positive results from the PARADIGM Study in ALS and Alzheimer's disease. The company is focused on advancing its treatments for neurodegenerative diseases, with plans for further research and clinical trials in the coming months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.74%
Tags
-
Rhea-AI Summary
Synaffix announces licensing agreement with ABL Bio to develop bispecific ADCs
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.02%
Tags
none
-
Rhea-AI Summary

HaemaLogiX and Lonza have entered a collaboration to manufacture KappaMab, a monoclonal antibody targeting multiple myeloma, at Lonza's new facility in Guangzhou, China. The agreement will leverage Lonza's regulatory expertise and manufacturing capabilities to support clinical trials for KappaMab. The drug has demonstrated a favorable safety profile in previous trials and has shown improved response rates when combined with lenalidomide. The first clinical batch is expected to be ready by Q4 2022, with trials scheduled to begin shortly thereafter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.83%
Tags
none

FAQ

What is the current stock price of LONZA GROUP UNSP/ADR (LZAGY)?

The current stock price of LONZA GROUP UNSP/ADR (LZAGY) is $58.89 as of January 3, 2025.

What is the market cap of LONZA GROUP UNSP/ADR (LZAGY)?

The market cap of LONZA GROUP UNSP/ADR (LZAGY) is approximately 43.2B.

What is Lonza Group AG UNSP/ADR known for?

Lonza Group AG UNSP/ADR is a global company specializing in life sciences and healthcare solutions.

What industries does Lonza operate in?

Lonza operates in pharmaceuticals, biotechnology, nutrition, and cosmetics sectors.

What sets Lonza apart from its competitors?

Lonza's focus on innovation, sustainability, and excellence in research and development distinguishes them in the industry.

Where does Lonza provide its products and services?

Lonza delivers high-quality solutions to customers worldwide through cutting-edge technologies and state-of-the-art facilities.

What is Lonza's commitment to sustainability?

Lonza is dedicated to sustainability in all aspects of its operations, ensuring responsible practices and environmental stewardship.

How does Lonza contribute to the healthcare industry?

Lonza's products and services play a crucial role in advancing healthcare, providing solutions for pharmaceuticals, biotechnology, and more.

What is Lonza's approach to research and development?

Lonza prioritizes excellence in research and development, driving innovation and delivering high-quality solutions to meet customer needs.

Why is Lonza considered a global leader in life sciences?

Lonza's global presence, cutting-edge technologies, and commitment to excellence have established them as a leader in life sciences and healthcare solutions.

What values guide Lonza's operations?

Lonza is guided by a commitment to innovation, sustainability, quality, and customer satisfaction in all aspects of its business.

How does Lonza contribute to global health and well-being?

Lonza's products and services support global health and well-being by providing essential solutions for pharmaceuticals, biotechnology, nutrition, and cosmetics.

What is Lonza's vision for the future?

Lonza aims to continue driving innovation, sustainability, and excellence in research and development to meet the evolving needs of customers and contribute to a healthier world.
LONZA GROUP AG UNSP/ADR

OTC:LZAGY

LZAGY Rankings

LZAGY Stock Data

43.16B
721.17M
0.71%
Diagnostics & Research
Healthcare
Link
United States of America
Basel